.Nature Medicine, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin resulted in boosted progression-free as well as overall survival, resulting in FDA commendation and also a new treatment option for individuals.